Microbial Nucleic Acid Detector Gets FDA Class II Designation
Published Date: 5/9/2025
Rule
Summary
The FDA is officially classifying a special device that detects and identifies tiny germs in patient samples using a cool glowing technique called FISH as a Class II device, meaning it’s safe and effective with some special rules. This change helps get these innovative tools to patients faster by cutting down red tape. The new rules took effect on May 9, 2025, and mainly affect companies making or using these devices in healthcare.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
FISH Microbial Test Moved to Class II
The FDA officially classified devices that detect microbial nucleic acids by fluorescence in situ hybridization (FISH) in clinical specimens as Class II (special controls). This order is effective May 9, 2025, and the classification was applicable on August 18, 2017. The device is subject to premarket notification under section 510(k) instead of automatic Class III premarket approval.
Required Design Verification and Validation Data
Manufacturers must provide detailed design verification and validation documentation to meet the special controls. Required items include device description, probe sequences and rationale, fluorophore and detection details, analytical studies (limit of detection, inclusivity, reproducibility, interference, cross-reactivity, specimen stability), and a clinical study with prospective (sequential) samples compared to accepted comparator methods.
De Novo Classification Enables Future 510(k) Predicates
Because FDA classified this device into Class II via the De Novo process, the device can serve as a predicate for future devices, allowing later sponsors to use the 510(k) pathway rather than a De Novo request or premarket approval. The FDA notes this can reduce regulatory burdens and enhance patient access to innovation.
Labeling Must Clarify Use and Limits
Device labeling must state the test is to be used along with clinical history, signs, symptoms, and other diagnostic tests. Labels must also explain how to interpret results and quality-control acceptance criteria, and must state that negative results do not rule out infection.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08149, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect Nucleic Acids From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections and Associated Resistance Marker(s)
The FDA is officially classifying devices that detect DNA from non-viral germs causing sexually transmitted infections (STIs) and their resistance markers as Class II, meaning they have special safety rules but fewer hurdles than the strictest category. This change helps companies bring these important tests to patients faster and safer, starting May 9, 2025. Labs, device makers, and patients will all benefit from quicker access to innovative STI testing without extra red tape.
Next: 2025-08151, Medical Devices; Hematology and Pathology Devices; Classification of the Coagulation System for the Measurement of Whole Blood Viscoelastic Properties in Perioperative Patients
The FDA is officially classifying a special blood test device used during surgery as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to new, helpful technology. The new rules took effect on May 9, 2025, and could save time and money for makers and users of these devices.